Screening of the transcriptional regulatory regions of vascular endothelial growth factor receptor 2 (VEGFR2) in amyotrophic lateral sclerosis

BMC Med Genet. 2007 Apr 24:8:23. doi: 10.1186/1471-2350-8-23.

Abstract

Background: Vascular endothelial growth factor (VEGF) has neurotrophic activity which is mediated by its main agonist receptor, VEGFR2. Dysregulation of VEGF causes motor neurone degeneration in a mouse model of amyotrophic lateral sclerosis (ALS), and expression of VEGFR2 is reduced in motor neurones and spinal cord of patients with ALS.

Methods: We have screened the promoter region and 4 exonic regions of functional significance of the VEGFR2 gene in a UK population of patients with ALS, for mutations and polymorphisms that may affect expression or function of this VEGF receptor.

Results: No mutations were identified in the VEGFR2 gene. We found no association between polymorphisms in the regulatory regions of the VEGFR2 gene and ALS.

Conclusion: Mechanisms other than genetic variation may downregulate expression or function of the VEGFR2 receptor in patients with ALS.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amyotrophic Lateral Sclerosis / genetics*
  • Down-Regulation
  • Exons
  • Female
  • Humans
  • Male
  • Middle Aged
  • Mutation
  • Polymerase Chain Reaction
  • Polymorphism, Restriction Fragment Length
  • Regulatory Elements, Transcriptional / genetics*
  • Sequence Analysis, DNA
  • Vascular Endothelial Growth Factor Receptor-2 / genetics*

Substances

  • Vascular Endothelial Growth Factor Receptor-2